TRPV4 and breast carcinoma: Both TRPV4 silencing and pharmacological inhibition of TRPV4 inhibited migration and invasion of the 4T07 breast cancer cell line expressing TRPV4, and 4α-PDD (a TRPV4 agonist) downregulated adherence-associated tumour suppressor genes in the 4T07 cells, further suggesting that TRPV4 increased the metastatic potential of the tumour (Lee et al., 2016).